Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Memorial Sloan Kettering Cancer Center patents


Recent patent applications related to Memorial Sloan Kettering Cancer Center. Memorial Sloan Kettering Cancer Center is listed as an Agent/Assignee. Note: Memorial Sloan Kettering Cancer Center may have other listings under different names/spellings. We're not affiliated with Memorial Sloan Kettering Cancer Center, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Memorial Sloan Kettering Cancer Center-related inventors


 new patent  Antibodies to muc16 and methods of use thereof

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) muc16 ectodomain polypeptide, b) muc16 cytoplasmic domain polypeptide, and c) muc16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which muc16 is overexpressed, such as cancer.. ... Memorial Sloan Kettering Cancer Center

Immunogenic wt-1 peptides and methods of use thereof

This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a wt1-expressing cancer, comprising heteroclitic peptides derived from the wt-1 protein.. . ... Memorial Sloan Kettering Cancer Center

Anisotropic particles, methods and uses thereof

The present disclosure, among other things, provides new technologies for preparation of anisotropic nanoparticle cores (e.g., anisotropic gold nanoparticle cores) and compositions thereof. Provided technologies show a number of advantages as compared with previously available options for preparing anisotropic nanoparticle cores, including, for example, that they typically utilize mild reaction conditions and, in many embodiments, only environmentally benign agents. ... Memorial Sloan Kettering Cancer Center

Anti-ctla-4 antibodies and methods of use thereof

The instant disclosure provides antibodies that specifically bind to ctla-4 (e.g., human ctla-4) and antagonize ctla-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.. ... Memorial Sloan Kettering Cancer Center

Hsp70 modulators and methods for making and using the same

The present invention, among other things, provides compounds and compositions thereof for use in the modulation of hsp70. In some embodiments, the present invention provides a method for inhibiting hsp70 activity. ... Memorial Sloan Kettering Cancer Center

Imaging of tumor-associated macrophages

Presented herein are methods and compositions for non-invasive imaging of tams with discoidal high-density lipoproteins to assess prognosis and therapy outcome. Tams are increasingly investigated in cancer immunology, and are considered a promising target for better and tailored treatment of malignant growths. ... Memorial Sloan Kettering Cancer Center

Macropinocytosis in cancer

Disclosed herein are compositions and methods for detecting and treating cancer. In some embodiments, the cancer is characterized by activation of ras.. ... Memorial Sloan Kettering Cancer Center

Systems and methods for determining optimum patient-specific antibody dose for tumor targeting

The present disclosure describes a non-linear compartmental model using pet-derived data to predict, on a patient-specific basis, the optimal therapeutic dose of cargo carrying antibody (e.g., hua33) such as radiolabeled antibody, the antigen occupancy, residency times in normal and malignant tissues, and the cancer-to-normal tissue (e.g., colorectal cancer-to-normal colon tissue) therapeutic index. In addition, the non-linear compartmental model can be readily applied to the development of strategies such as multi-step targeting (mst) designed to further improve the therapeutic indices of rit.. ... Memorial Sloan Kettering Cancer Center

Methods and compositions for theranostic nanoparticles

Disclosed are compositions and methods for identifying a solid tumor cell target. Compositions and methods for treating prostate cancer are also disclosed. ... Memorial Sloan Kettering Cancer Center

Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy

Disclosed herein are methods of treating an ebv-lpd (epstein-barr virus-associated lymphoproliferative disorder) in a human patient who has failed combination chemotherapy to treat the ebv-lpd and/or radiation therapy to treat the ebv-lpd, comprising administering to the human patient a population of allogeneic t cells comprising ebv-specific t cells.. . ... Memorial Sloan Kettering Cancer Center

Compositions and methods for treatment of glioma

In certain embodiments the present invention provides methods useful in the treatment of glioma, such as glioblastoma, such methods comprising administering to a subject in need thereof a csf-ir inhibitor together with one or more additional active agents such as igf-ir inhibitors, pi3k inhibitors, il4 inhibitors, nfat inhibitors, and/or stat6 inhibitors. In certain embodiments the present invention provides pharmaceutical compositions comprising a csf-ir inhibitor together with one or more of such additional active agents.. ... Memorial Sloan Kettering Cancer Center

Newcastle disease viruses and uses thereof

Described herein are chimeric newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. ... Memorial Sloan Kettering Cancer Center

Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors

The present disclosure relates to modified vaccinia ankara (mva) virus or mvaae3l delivered intratumorally or systemically as an anticancer immunotherapeutic agent, alone, or in combination with one or more immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to mobilizing the host's immune system to mount an immune response against the tumor.. ... Memorial Sloan Kettering Cancer Center

Synergistic cancer treatment

The use of mitogen activated kinase inhibition therapy in combination with receptor tyrosine kinase therapy for the treatment of cancer is described.. . ... Memorial Sloan Kettering Cancer Center

02/01/18 / #20180028514

Compositions and methods for treatment of edema

Provided are pharmaceutical compositions and methods of treating or preventing edema, using an anti-t cell agent, an anti-tgf-β agent, or an anti-angiotensin agent, preferably a combination of at least two such agents. The pharmaceutical compositions can be formulated for systemic or local administration, and are preferably administered topically.. ... Memorial Sloan Kettering Cancer Center

02/01/18 / #20180028128

Methods and systems for retrospective internal gating

The present invention, in one form, is a method for deriving respiratory gated pet image reconstruction from raw pet data. In reconstructing the respiratory gated images in accordance with the present invention, respiratory motion information derived from individual voxel signal fluctuations, is used in combination to create usable respiratory phase information. ... Memorial Sloan Kettering Cancer Center

01/25/18 / #20180021265

Compositions and methods for nanoparticle-based drug delivery and imaging

Methods and compositions described herein use polysaccharide nanoparticles (or polysaccharide-coated nanoparticles) to retain and deliver unaltered therapeutic agents to sites of disease. The polysaccharide nanoparticles are non-covalently associated with the unaltered therapeutic agent. ... Memorial Sloan Kettering Cancer Center

01/25/18 / #20180021259

Dye-stabilized nanoparticles and methods of their manufacture and therapeutic use

Described herein are nanoparticles which are largely made of (e.g., 90 wt. %) hydrophobic drugs and are stabilized by water soluble dyes. ... Memorial Sloan Kettering Cancer Center

12/21/17 / #20170363635

Methods of treating and prognosing nonhematopoietic malignant tumors

Provided herein are methods of treating a nonhematopoietic malignant tumor in a patient and methods of prognosing a nonhematopoietic malignant tumor in a patient, comprising administering to the patient a therapeutically effective amount of an agent that preferentially kills or inhibits proliferation or activity of leukocytes relative to nonhematopoietic cells.. . ... Memorial Sloan Kettering Cancer Center

11/30/17 / #20170342073

Small-molecule hsp90 inhibitors

Hsp90 inhibitors havin are rovided havin the formula: (i) with a 2′,4′,5′-substitution pattern on the right-side aryl moiety. X1 represents two substituents, which may be the same or different, disposed in the 4′ and 5′ positions on the aryl group, wherein x1 is selected from halogen, alkyl, alkoxy, halogenated alkoxy, hydroxyalkyl, pyrollyl, optionally substituted aryloxy, alkylamino, dialkylamino, carbamyl, amido, alkylamido dialkylamido, acylamino, alkylsulfonylamido, trihalomethoxy, trihalocarbon, thioalkyl, so2alkyl, coo alkyl, kh2, oh, cn, so2x5, no2, no, c═sr2 nso2x5, c═or2, where x5 is f, nh2, alkyl or h, and r2 is alkyl, nh2, nh-alkyl or o-alkyl, c1 to c6 alkyl or alkoxy; or wherein x1 has the formula —o—(ch2)n—o—, wherein n is an integer from o to 2, preferably 1 or 2, and one of the oxygens is bonded at the 5′-position and the other at the 4′-position of the aryl ring. ... Memorial Sloan Kettering Cancer Center

11/23/17 / #20170334966

Anti-tumor antibody-tumor suppressor fusion protein compositions and methods of use for the treatment of cancer

The present invention is directed to methods and compositions for treating cancer, including, hematologic malignancies, such as b-cell malignancies, with anti-tumor antibody-tumor suppressor fusion proteins in order to selectively restore tumor suppressor gene function to cancer cells in which such tumor suppressor gene function has been lost. The present invention is also directed to methods and compositions for diagnosing cancer and for predicting and assessing response to treatment.. ... Memorial Sloan Kettering Cancer Center

11/23/17 / #20170334951

Immunogenic wt-1 peptides and methods of use thereof

This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a wt-1-expressing cancer, comprising peptides derived from the wt-1 protein.. . ... Memorial Sloan Kettering Cancer Center

11/16/17 / #20170330740

Method for enhancing electrospray

Provided herein, among other things, is a method of ionizing a first stream of liquid by an electrospray ion source having a nebulizer, wherein the first stream of liquid may comprise an analyte. In some embodiments, the method may comprise: a) providing the first stream of liquid to the nebulizer; b) adding a second stream of liquid to the first stream of liquid, wherein the second stream of liquid comprises a co-solvent that has a relatively high boiling point and an enhancement solvent that a relatively high boiling; and c) nebulizing and ionizing the resulting liquid.. ... Memorial Sloan Kettering Cancer Center

11/09/17 / #20170319683

Methods of selecting t cell line and donor thereof for adoptive cellular therapy

Disclosed herein are methods of selecting an allogeneic t cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer. Also disclosed are methods of selecting a donor from whom to derive an allogeneic t cell line for therapeutic administration to a patient having or suspected of having a pathogen or cancer.. ... Memorial Sloan Kettering Cancer Center

10/26/17 / #20170304470

Hsp90-targeted inflammation and infection imaging and therapy

The present invention provides new methods for inflammation and infection imaging and related medical applications thereof. In some embodiments, the present invention provides a method for the diagnosis of inflammation and/or infection. ... Memorial Sloan Kettering Cancer Center

09/21/17 / #20170266327

Radiohalide-labeled targeted diagnostics and therapeutics

Disclosed are chemical entities of formula (i) wherein r1, r2 and n are defined herein, and methods of use thereof. These chemical entities are radiative emitters and are useful, e.g., as therapeutic agents for the treatment of, or as diagnostic (e.g., imaging) agents for cancers, e.g., cancers in which parp1 is overexpressed.. ... Memorial Sloan Kettering Cancer Center

09/07/17 / #20170253660

Anti-gd2 antibodies

In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific anti-gd2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of gd2-related diseases, in particular, neuroblastoma.. ... Memorial Sloan Kettering Cancer Center

09/07/17 / #20170252433

Psma-related therapies

The present invention provides methods of treating disease by modulation of psma activity. Such modulations can lead to, for example, alterations in cancer tumor metabolism, oxygenation, vascularization, and metastasis. ... Memorial Sloan Kettering Cancer Center

08/24/17 / #20170240637

Antibodies, compositions, and uses

The present disclosure describes anti-b7h3 antibody agents and uses relating thereto. Among other things, the present disclosure demonstrates particular immunomodulatory effectiveness of certain such antibodies. ... Memorial Sloan Kettering Cancer Center

08/17/17 / #20170233352

Hsp70 modulators and methods for making and using the same

The present invention provides compounds i and ii and compositions thereof for use in the modulation of hsp70. In some embodiments, the present invention provides a method for inhibiting hsp70 activity. ... Memorial Sloan Kettering Cancer Center

07/27/17 / #20170210819

Bispecific her2 and cd3 binding molecules

Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to her2, a receptor tyrosine kinase, and to cd3, a t cell receptor, and mediate t cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating her2-related cancers.. ... Memorial Sloan Kettering Cancer Center

05/18/17 / #20170135766

Apparatus, system and method for providing laser steering and focusing for incision, excision and ablation of tissue in minimally-invasive surgery

Provided and described herein are exemplary embodiments of apparatus, system, computer-accessible medium, procedure and method according to the present disclosure which can be used for providing laser steering and focusing for e.g., incision, excision and/or ablation of tissue in minimally-invasive surgery. For example, an exemplary apparatus is provided that can include at least one optical element which can be configured to refract and/or diffract light provided in a structure which can be configured to be inserted into a body, where at least one of the optical element(s) is structured to receive the light at a first angle and generate a refracted and/or diffracted light at a second angle which can be different from the first angle relative to an optical axis. ... Memorial Sloan Kettering Cancer Center

05/11/17 / #20170130199

Methods for neural conversion of human embryonic stem cells

The present invention relates generally to the field of cell biology of stem cells, more specifically the directed differentiation of pluripotent or multipotent stem cells, including human embryonic stem cells (hesc), somatic stem cells, and induced human pluripotent stem cells (hipsc) using novel culture conditions. Specifically, methods are provided for obtaining neural tissue, floor plate cells, and placode including induction of neural plate development in hescs for obtaining midbrain dopamine (da) neurons, motorneurons, and sensory neurons. ... Memorial Sloan Kettering Cancer Center

03/30/17 / #20170087159

Platelet-derived growth factor receptor mutations and compositions and methods relating thereto

In certain embodiments the present invention involves methods of killing tumor cells that comprise an oncogenic pdgfr mutation, and methods of treating subjects having tumors that comprise such tumor cells. In some embodiments such methods involve using pi3k inhibitors, or a combination of a pi3k inhibitor and an mtor inhibitor, or a dual pi3k/mtor inhibitor. ... Memorial Sloan Kettering Cancer Center

03/23/17 / #20170081409

Anti-pd-1 antibodies and methods of use thereof

The instant disclosure provides antibodies that specifically bind to human pd-1 and antagonize pd-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.. ... Memorial Sloan Kettering Cancer Center

01/26/17 / #20170022475

Modulating cell proliferation and pluripotency

Disclosed herein are compositions, systems, and methods for modulating proliferation, differentiation and pluripotency of cells.. . ... Memorial Sloan Kettering Cancer Center








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Memorial Sloan Kettering Cancer Center in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Memorial Sloan Kettering Cancer Center with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###